Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood
Authors:
Open Access
- 3 January 2025
- journal article
- letter
- Published by Springer Nature in Biomarker Research
- Vol. 13 (1) , 1-5
Abstract
Although chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy against leukemic cells, it still has critical limitations. CAR macrophage has been regarded as a potential alternative to CAR T cells. However, due to the difficulties in gene transduction into macrophages, the production of primary human CAR macrophages from peripheral blood mononuclear cells (PBMC) using lentivirus is highly challenging. Here, we report on how to generate CAR macrophages from human PBMC with lentiviral particles. Using our lentiviral protocol, we produced functional CAR macrophages to lyse and phagocytose target cancer cells efficiently.Keywords
This publication has 12 references indexed in Scilit:
- A second-generation M1-polarized CAR macrophage with antitumor efficacyNature Immunology, 2023
- RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trialeClinicalMedicine, 2023
- M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumorsJournal of Translational Medicine, 2023
- Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapiesStem Cell Reports, 2023
- Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer TherapyAdvanced Materials, 2021
- Human chimeric antigen receptor macrophages for cancer immunotherapyNature Biotechnology, 2020
- Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trialOncoImmunology, 2020
- Tumor-Associated Macrophages: From Mechanisms to TherapyImmunity, 2014
- Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage RestrictionPLOS Pathogens, 2008
- Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivoGene Therapy, 2006